Researchers have developed a novel compound that could transform the way we treat Alzheimer's disease, offering not just a new weapon but potentially a new strategy for battling the most common form of dementia worldwide. While current drugs for Alzheimer's mostly focus on removing amyloid-beta plaques associated with the disease, the new compound takes a fundamentally different approach, instead targeting a specific enzyme to therapeutically reprogram the epigenome of neurons – a series of